UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 31, 2007
Neurocrine Biosciences, Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
0-22705
|
|
33-0525145 |
| (State or other jurisdiction of
|
|
(Commission File Number)
|
|
(I.R.S. Employer |
| incorporation)
|
|
|
|
Identification No.) |
| |
|
|
| 12790 El Camino Real |
|
|
| San Diego, California
|
|
92130 |
| (Address of principal executive offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code: (858) 617-7600
Not Applicable.
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment
of Certain Officers; Compensatory Arrangements of Certain Officers.
(e) On May 31, 2007, our Board of Directors approved an amendment to our 2003 Incentive Stock Plan
(the “2003 Plan”). The amendment (i) limits the aggregate number of shares of Common Stock with
respect to which awards of Restricted Stock, Restricted Stock Units and Stock Bonuses (each as
defined in the 2003 Plan) or a combination thereof shall be made under the 2003 Plan to 50% of the
aggregate number of shares of Common Stock available under the 2003 Plan and (ii) eliminates
promissory notes as a potentially permissible method of consideration to be paid for shares of
Common Stock issuable upon exercise of awards granted under the 2003 Plan. A copy of the 2003
Plan, as amended, is attached as Exhibit 10.1 hereto and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| |
|
|
| Number |
|
Description |
|
|
|
10.1
|
|
Neurocrine Biosciences, Inc. 2003 Incentive Stock Plan, as amended. |